Tracked deals
5
5 tracked deals across 2020-2022.
Vevey, Vaud, Switzerland
Formerly known as NHSc, Nestle Health Science, Nestle Health Science (NHSc)
Nutrition & Health by Nestlé is Nestlé’s nutrition and health business, succeeding the Nestlé Health Science identity following a 2026 reorganization. Its portfolio spans science-based consumer nutrition and supplements, medical nutrition, and health-focused products and solutions.
Tracked deals
5
5 tracked deals across 2020-2022.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
5 buyout
Last 3 years
Supporting Data
Nestlé Health Science has agreed to acquire a majority stake in Orgain, the U.S. plant-based nutrition company, from founder Dr. Andrew Abraham and Butterfly Equity; both sellers will retain minority ownership positions. Dr. Andrew Abraham will remain CEO of Orgain and the deal will let Nestlé Health Science expand its portfolio of clean, plant-based nutrition products globally; the transaction is subject to customary regulatory approvals.
Nestlé (via Nestlé Health Science) agreed to acquire the core vitamin and supplement brands of The Bountiful Company from KKR and Carlyle for $5.75 billion, integrating brands such as Nature's Bounty, Solgar, Puritan's Pride and Osteo Bi‑Flex into its NHSc portfolio. The deal (expected/closed in H2 2021) brings roughly 4,000–4,500 employees into Nestlé Health Science and establishes Nestlé as a global leader in vitamins, minerals and nutritional supplements across mass retail, specialty retail and e‑commerce.
TSG Consumer Partners’ partner company Nuun has entered into an agreement to be acquired by Nestlé Health Science. Terms were not disclosed, and the transaction is expected to close in the second half of 2021.
Nestlé Health Science (NHSc), via a Nestlé S.A. acquisition subsidiary (Société des Produits Nestlé S.A.), agreed to acquire Aimmune Therapeutics for USD34.50 per share in cash, valuing the company at approximately USD2.6 billion. NHSc already owned ~25.6% of Aimmune; the tender offer is expected to close in Q4 2020 and will expand Nestlé's portfolio with Aimmune's FDA-approved peanut allergy therapy Palforzia.
Nestlé Health Science (NHSc), a subsidiary of Nestlé, agreed to acquire a majority stake in Vital Proteins, the US market leader in collagen-based supplements, beverages and food products. Vital Proteins will continue to operate as a standalone business under CEO Kurt Seidensticker, with the deal intended to accelerate global expansion and product innovation.
Turn tracked acquisition activity into an outreach-ready buyer list.